Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma

Crizotinib is the first approved ALK inhibitor in advanced, ALK-positive non-small cell lung cancer (NSCLC). When administered in first line, median progression-free survival (mPFS) was 10.9 months (ms) with crizotinib versus 7.0 ms with best cytostatic chemotherapy. Overall response rate was 74% with crizotinib versus 45% with chemotherapy (1).